×
For best experience we recommend to activate Javascript in your browser.
Recombinant GFRA3 (Nadecnemab Biosimilar) antibody
Reactivity: Human
ELISA, FACS, BLI, Func, SPR
Host: Human
Monoclonal
unconjugated
Recombinant Antibody
Product Details anti-GFRA3 (Nadecnemab Biosimilar) Antibody
(hide)
Target
See all GFRA3 (Nadecnemab Biosimilar) products
GFRA3 (Nadecnemab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for GFRA3 (Nadecnemab Biosimilar) antibodies
Human
Expression System
CHO Cells
Clonality
All clonalities for GFRA3 (Nadecnemab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for GFRA3 (Nadecnemab Biosimilar) antibodies
This GFRA3 (Nadecnemab Biosimilar) antibody is un-conjugated
Application
ELISA, Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Purpose
Anti-GFRA3 Reference Antibody (nadecnemab)
Characteristics
Anti-GFRA3 Reference Antibody (nadecnemab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG4
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for GFRA3 (Nadecnemab Biosimilar)
(hide)
Target
GFRA3 (Nadecnemab Biosimilar)
Abstract
GFRA3 (Nadecnemab Biosimilar) Products
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
O60609
Recently viewed
(hide)